Some Indicators of Carbohydrate Metabolism in Individuals after the Abolition of the Use of Anabolic Androgenic Steroids

Abstract

Background: The use of anabolic androgenic steroids to form a sports figure is widespread. Anabolic androgenic steroids (AAS) are used in higer doses than in therapeutic practice. Studies of the side effects of AAS on carbohydrate metabolism are hampered due to the self-over-the-counter use of AAS. Hypothesis: We assumed that with the abolition of AAS, the effect of high doses of testosterone (Ts) and nandrolone decanoate on the utilization of glucose is reduced. Methods: After informational lectures among visitors in sports clubs in St. Petersburg on the impact of the AAS application on health, patients who expressed desire were included in the study. The inclusion criterion was the use of preparations of 19-nortestosterone with a course of 6 to 8 weeks in a weekly dosage of 300 to 700 mg in combination with Ts propionate and Ts enanthate, as well as the rejection of the subsequent use of anabolic steroids. BMI, HbA1c, immunoreactive insulin (IRI) and Fasting plasma glucose (FG), homeostatic model assessment-insulin resistance HOMA-IR were compared before and 3 months after the abolition of all AAS, while maintaining the previous physical activity and eating habits. Results: We examined 24 pts (18M), age 27 ± 3.6. The average period of use of AAS is 7.3 weeks. After the abolition of the AAS, the IMB increased (mean difference = 4.7 kg, p = 0.012). The metabolism of glucose has changed in the direction of an increase in all the indicators considered: FG (mean difference = 1.02 mmol / l, p = 0.047), IRI (mean difference = 9.83, p = 0.023), HOMA-IR (mean difference = 7.31, p = 0.015) and HbA1c (mean difference = 0.25%, p = 0.031). However, no violations of glucose metabolism were detected in any case. Conclusions: The abolition of AAS in athletes caused an increase in body weight and a shift in all glucose metabolism rates closer to the upper normal values, this trend deserves further study. Disclosure M.P. Lykhonosov: None. A.Y. Babenko: None.